New hope for rare bleeding disorder: drug VAD044 targets nosebleeds
NCT ID NCT05406362
First seen Apr 04, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces nosebleeds. The second part is an open-label extension to check long-term safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospices Civils de Lyon
Lyon, France
-
Hospital Universiati De Bellvitge
Barcelona, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ospedale Maggiore di Crema
Crema, Italy
-
St. Antonius Hospital
Nieuwegein, Netherlands
-
Universitair Ziekenhuis Gent
Ghent, Belgium
Conditions
Explore the condition pages connected to this study.